Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema

JAMA Ophthalmology Author Interviews
02/02/2023 13 min
Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema

Listen "Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema"

Descargar episodio Ver en sitio original

Episode Synopsis

Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.

More episodes of the podcast JAMA Ophthalmology Author Interviews

Diabetes in the Donor and Descemet Membrane Endothelial Keratoplasty Success at 1 Year 17/10/2025
Smooth Pursuit Velocity After a Season of Repetitive Head Impacts in American Football Players 18/09/2025
Mammalian Target Rapamycin Inhibition for Proliferative Vitreoretinopathy 07/08/2025
Steroids and Cross-Linking for Ulcer Treatment 24/07/2025
From the JAMA Network: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension 17/07/2025
Gender Differences in Case Volume Among Ophthalmology Resident Graduates, 2014-2023 01/05/2025
Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab 06/03/2025
Shedding LiGHT on Selective Laser Trabeculoplasty 20/02/2025
Ophthalmic Complications Associated With Semaglutide and Tirzepatide 30/01/2025
Ultra-Widefield Optical Coherence Tomography Beyond the Ora Serrata in ROP 26/12/2024
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA